Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 6, Issue 1, Pages 4-15
Publisher
SAGE Publications
Online
2013-11-08
DOI
10.1177/1758834013510589
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness of Continuation Maintenance Pemetrexed After Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Estimates From the Perspective of the Chinese Health Care System
- (2013) Xiaohui Zeng et al. CLINICAL THERAPEUTICS
- Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
- (2013) Erzsébet Juhász et al. EUROPEAN JOURNAL OF CANCER
- Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea
- (2013) David E. Gerber et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
- (2013) Fabrice Barlesi et al. JOURNAL OF CLINICAL ONCOLOGY
- PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
- (2012) Cesare Gridelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
- (2012) Maurice Pérol et al. JOURNAL OF CLINICAL ONCOLOGY
- LATE-BREAKING ABSTRACTS
- (2012) NA Journal of Thoracic Oncology
- Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2012) Cesare Gridelli et al. Journal of Thoracic Oncology
- Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study
- (2012) Chandra P Belani et al. LANCET ONCOLOGY
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- (2012) Tudor Ciuleanu et al. LANCET ONCOLOGY
- A Systemic Approach to Containing Health Care Spending
- (2012) Ezekiel Emanuel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer
- (2011) Fausto Petrelli et al. ANTI-CANCER DRUGS
- AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)
- (2011) F Barlesi et al. EUROPEAN JOURNAL OF CANCER
- Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System
- (2011) Klazien Matter-Walstra et al. VALUE IN HEALTH
- Pem and the Cost of Multicycle Maintenance
- (2010) Peter A. Learn et al. Journal of Thoracic Oncology
- Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
- (2010) Robert Klein et al. Journal of Thoracic Oncology
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer
- (2009) Jyoti D. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- (2009) Tudor Ciuleanu et al. LANCET
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2008) Panos M. Fidias et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard
- (2008) Chris P. Lee et al. VALUE IN HEALTH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation